HRYZT 102
Alternative Names: HRYZ-T102Latest Information Update: 30 Jul 2024
At a glance
- Originator HengRui YuanZheng Bio-Technology
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cancer; Solid tumours
Most Recent Events
- 23 Jul 2024 Phase-I clinical trials in Liver cancer (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT06515314)
- 23 Jul 2024 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT06515314)
- 17 Jul 2024 HengRui YuanZheng Bio-Technology plans a phase I/II trial for Liver cancer in 2025 (HengRui YuanZheng Bio-Technology pipeline, July 2024)